Overview

Useful For
Rapid detection of BK virus DNA

Method Name
Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization

NY State Available
Yes

Specimen

Specimen Type
Plasma EDTA

Specimen Required
Collection Container/Tube: Lavender top (EDTA)

Submission Container/Tube: Screw-capped, sterile container

Specimen Volume: 1 mL

Collection Instructions: Spin down and separate plasma within 24 hours of collection.

Forms
If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.

Specimen Minimum Volume
0.5 mL

Reject Due To

| Gross hemolysis | Reject |

Specimen Stability Information

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma EDTA</td>
<td>Refrigerated (preferred)</td>
<td>14 days</td>
</tr>
<tr>
<td></td>
<td>Frozen</td>
<td>14 days</td>
</tr>
</tbody>
</table>

Clinical and Interpretive

Clinical Information
Polyomaviruses are small (45 nm, approximately 5,000 base pairs), DNA-containing viruses and include 3 closely
related viruses of clinical significance, Simian virus 40 (SV-40), JC virus (JCV), and BK virus (BKV). SV-40 naturally infects rhesus monkeys but can infect humans, while BKV and JCV cause productive infection only in humans. Acquisition of BKV begins in infancy. Serological evidence of infection by BKV is present in 37% of individuals by 5 years of age and over 80% of adolescents.

BKV is an important cause of interstitial nephritis and associated nephropathy (BKVAN) in recipients of kidney transplants. Up to 5% of renal allograft recipients can be affected, and among those patients the average time from transplant to diagnosis is about 40 weeks (range 6-150). PCR analysis of BKV DNA in the plasma is the most widely used blood test for the laboratory diagnosis of BKV-associated nephropathy. Importantly, the presence of BKV DNA in blood reflects the dynamics of the disease: the conversion of plasma from negative to positive for BKV DNA after transplantation, the presence of DNA in plasma in conjunction with the persistence of nephropathy, and its disappearance from plasma after the reduction of immunosuppressive therapy. Viral loads of above 10,000 copies/mL in plasma may indicate a risk for BKVAN (see QBK / BK Virus, Molecular Detection, Quantitative, PCR, Plasma).

Reference Values

Interpretation

Results of plasma tests are reported in terms of the presence or absence of BK virus (BKV).

Detection of BKV DNA in clinical specimens may support the clinical diagnosis of renal or urologic disease due to BKV. Correlation of qualitative results with clinical presentation and BK viral load in urine and/or plasma is recommended.

Cautions

A negative result does not rule out the possibility of BK virus (BKV) infection.

This assay is for use in patients with appropriate risk factors for BKV-associated disease and is not indicated for screening of asymptomatic patients.

Supportive Data

The following validation supports the use of this assay for clinical testing.

Accuracy/Diagnostic Sensitivity and Specificity:

Results from this real-time PCR assay on the LightCycler (LC PCR) were compared to a previous PCR assay (directed to VP2 region of the polyoma virus based on a published method) on 112 plasma specimens and 108 urine specimens. Using the previous method as the gold standard, the diagnostic sensitivity and specificity is 94% and 90% for plasma and 100% and 100% for urine, respectively. The discrepant samples had low viral DNA copy numbers (<5,000 copies/mL) and may not have been reproducible.

Supplemental Data (Spiking Studies):

To supplement the above data, 30 negative plasma and urine specimens were spiked with BK virus (BKV)-positive control plasmid near the limit of detection (LoD). The 30-spiked specimens were run in a blinded manner along with 57 plasma and 58 urine negative (nonspiked) specimens. 100% of the spiked specimens were positive and 100% of the nonspiked specimens were negative.

Analytical Sensitivity/LoD:
Test Definition: LCBKP
BK Virus DNA by PCR, P

The LoD of this assay is 244 DNA target copies per mL in urine and plasma.

Analytical Specificity:

No PCR signal was obtained from the extracts of a variety of human viruses that can be found in urine or plasma, including cytomegalovirus, Epstein-Barr virus, human herpesvirus-6, enterovirus, adenovirus, and mumps virus.

Precision:

Inter-assay precision was 100% and intra-assay precision was 100%.

Reference Range:

The reference range of BKV in plasma is negative.

In renal transplant patients, plasma viral load copies of >10,000 copies/mL may indicate increased risk of BKV disease. Therefore, a quantitative test may be appropriate in this population (see QBK / BK Virus, Molecular Detection, Quantitative, PCR, Plasma).

Reportable Range:

This is a qualitative assay and the results are reported as negative or positive for targeted BKV.

Clinical Reference

Performance

Method Description
Viral nucleic acid is extracted by the MagNA Pure automated instrument (Roche Applied Science) from the specimen. Primers are directed to the large T antigen gene, which is a conserved sequence specific for BK virus.
This assay does not detect JC virus or SV-40 (other polyomaviruses). The LightCycler instrument (Roche Applied Science) amplifies and monitors the development of target nucleic acid sequences after the annealing step during PCR cycling. This automated PCR system can rapidly detect amplicon development through stringent air-controlled temperature cycling in capillary cuvettes. The detection of amplified products is based on the fluorescence resonance energy transfer (FRET) principle. For FRET product detection, a hybridization probe with a donor fluorophore, fluorescein, on the 3'-end is excited by an external light source and emits light that is absorbed by a second hybridization probe with an acceptor fluorophore, LC-Red 640, at the 5'-end. The acceptor fluorophore then emits a light of a different wavelength that can be measured with a signal that is proportional to the amount of specific PCR product. (Unpublished Mayo method)

**PDF Report**  
No

**Day(s) and Time(s) Test Performed**  
Monday, Wednesday, Friday; 6 a.m.

**Analytic Time**  
Monday through Thursday: 2 days Friday, Saturday: 3 days

**Maximum Laboratory Time**  
5 days

**Specimen Retention Time**  
1 week

**Performing Laboratory Location**  
Rochester

**Fees and Codes**

**Fees**  
- Authorized users can sign in to [Test Prices](#) for detailed fee information.  
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.  
- Prospective clients should contact their Regional Manager. For assistance, contact [Customer Service](#).

**Test Classification**  
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

**CPT Code Information**  
87798

**LOINC® Information**

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LCBKP</td>
<td>BK Virus DNA by PCR, P</td>
<td>32362-6</td>
</tr>
<tr>
<td>Result ID</td>
<td>Test Result Name</td>
<td>Result LOINC Value</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>56084</td>
<td>BK Virus PCR, P</td>
<td>32362-6</td>
</tr>
</tbody>
</table>